Literature DB >> 26807419

The evolving evidence for the efficacy and safety of charged particle therapy for hepatocellular carcinoma-a commentary.

Jillian Gunther1, Sunil Krishnan1.   

Abstract

Entities:  

Year:  2015        PMID： 26807419      PMCID： PMC4701530          DOI： 10.3978/j.issn.2305-5839.2015.12.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

Review 1.  Charged-particle therapy for hepatocellular carcinoma.

Authors:  Heath D Skinner; Theodore S Hong; Sunil Krishnan
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Superiority of charged particle therapy in treatment of hepatocellular carcinoma (Regarding Qi W.X. et al. charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis).

Authors:  Hideya Yamazaki; Satoaki Nakamura; Gen Suzuki; Norihiro Aibe; Ken Yoshida
Journal:  Radiother Oncol       Date:  2015-11-17       Impact factor: 6.280

3.  Protons or photons for hepatocellular carcinoma? Let's move forward together.

Authors:  Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-01       Impact factor: 7.038

Review 4.  Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review.

Authors:  Francesco Dionisi; Lamberto Widesott; Stefano Lorentini; Maurizio Amichetti
Journal:  Radiother Oncol       Date:  2014-02-20       Impact factor: 6.280

5.  Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy.

Authors:  Ja Young Kim; Young Kyung Lim; Tae Hyun Kim; Kwang Hyun Cho; Sang Hyoun Choi; Hojin Jeong; Dae Woong Kim; Jung Hoon Park; Dong Ho Shin; Se Byeong Lee; Sang Soo Kim; Joo-Young Kim; Dae Yong Kim; Joong-Won Park
Journal:  Acta Oncol       Date:  2015-03-13       Impact factor: 4.089

6.  Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons.

Authors:  Saumil J Gandhi; Xing Liang; Xuanfeng Ding; Timothy C Zhu; Edgar Ben-Josef; John P Plastaras; James M Metz; Stefan Both; Smith Apisarnthanarax
Journal:  Pract Radiat Oncol       Date:  2015-02-18

7.  Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma.

Authors:  Timothy M Pawlik; Keith A Delman; Jean-Nicolas Vauthey; David M Nagorney; Irene Oi-Lin Ng; Iwao Ikai; Yoshio Yamaoka; Jacques Belghiti; Gregory Y Lauwers; Ronnie T Poon; Eddie K Abdalla
Journal:  Liver Transpl       Date:  2005-09       Impact factor: 5.799

8.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

Review 9.  Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.

Authors:  Su Jong Yu; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2015-06-18

Review 10.  Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Shen Fu; Qing Zhang; Xiao-Mao Guo
Journal:  Radiother Oncol       Date:  2014-12-09       Impact factor: 6.280
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.